Résumé
Une étude randomisée en simple aveugle a été réalisée pour évaluer l’efficacité de l’association Ganoderma lucidum+Coriolus versicolor+Lentinus edodes (GCL ; 61 patients) donnée pendant deux mois versus placebo sous la forme de Laetiporus sulfureus avec un mélange de 8 huiles essentielles (LS+HE ; seulement 1/8e de goutte d’HE/j ; 32 patients) sur la disparition du portage buccal d’EBV. GCL diminue de 80,3% le portage EBV buccal versus 6,3% pour le mélange LS+HE (p<0,001). Ce mélange de trois mycelia est très prometteur pour la prévention du portage chronique actif d’EBV. Cette étude préliminaire doit être complétée, pour vérifier ce résultat et pour répondre à de nombreuses questions émergentes : nécessité d’un traitement prolongé pour maintenir la disparition virale ? Effet de GCL sur les co-infections virales intrabuccales ?
Abstract
A randomised single-blind study was performed to investigate the efficacy of Ganoderma lucidum +Coriolus versicolor+Lentinus edodes (GCL; 61 patients), given two months, versus placebo i.e. Laetiporus sulfureus associated with eight essential oils (LS+HE; only 1/8 drop per day; 32 patients) against the oral reactivation of EBV with detectable DNA-EBV in oral swabs. GCL decreased by 80.3% le presence of DNA-EBV in oral swabs versus 6.3% for LS+HE (p<0.001). GCL is a harmless and promising association of mycelia which could prevent EBV induced-diseases. This preliminary study should be completed in order to increase the number of inclusions and confirm this finding. Additional queries may be tackled: should prevention require prolonged therapy with reduced dosage or may GCL participate to the eradication of other viruses such as papillomavirus, HSV1, HSV2 or cytomegalovirus?
Références
Ascherio A (2013) Environmental factors for multiple sclerosis. Expt Rev Neurother 13 (12 suppl): 3–9
Iizasa H, Nanbo A, Nishikawa J, et al. (2012) Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses 12: 3420–39
Molyneux EM, Rochford R, Griffin B, et al. (2012) Burkitt’s lymphoma. Lancet 379: 1234–44
Okano M, Gross TG (2012) Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection. Am J Med Sci 6: 483–9
Lossius A, Johansen JN, Torkildsen Ø, et al. (2012) Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. Viruses 12: 3701–30
Grinde B (2013) Herpes viruses: latency and reactivation — viral strategies and host response. J Oral Microbiol 25: 5
Donatini B (2010) Prevention of recurrence of herpes virus infection with Ganoderma lucidum plus Coriolus versicolor. Phytothérapie 4: 255–258
Hijikata Y, Yamada S, Yasuhara A (2007) Herbal mixtures containing the mushroom Ganoderma lucidum improve recovery time in patients with herpes genitalis and labialis. J Altern Complement Med 9: 985–7
Monma Y, Kawana T, Shimizu F (1997) In vitro inactivation of herpes simplex virus by a biological response modifier, PSK. Antiviral Res 3: 131–8
Razumov IA, Kazachinskaia EI, Puchkova LI, et al. (2013) Protective activity of aqueous extracts from higher mushrooms against Herpes simplex virus type-2 on albino mice model. Antibiot Khimioter 9–10: 8–12
Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 1: 117–22
Okada M, Minamishima Y (1987) The efficacy of biological response modifiers against murine cytomegalovirus infection in normal and immunodeficient mice. Microbiol Immunol 1: 45–57
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Donatini, B. Diminution de l’expression du virus d’Epstein Barr (EBV) dans la muqueuse gingivale par la prise durant deux mois de Ganoderma lucidum, Coriolus versicolor et Lentinus edodes . Phytothérapie 13, 231–233 (2015). https://doi.org/10.1007/s10298-015-0952-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10298-015-0952-4